OncoSil Files Application For Australian Manufacturing, Targets FY27 Production
OSL: $0.680 +0.00% · MC: $24M
OncoSil Medical has applied to add Cyclotek’s Macquarie Park facility to its existing certification, a step towards commercial production targeted for the second half of FY27, subject to regulatory approval. The company says the facility is designed to expand production capacity and improve manufacturing efficiency and gross margins as volumes grow, while keeping capital intensity below 5% at full capacity; Cyclotek achieved ISO 13485 certification in September.

Comments